Hypericin
- Generic Name
- Hypericin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H16O8
- CAS Number
- 548-04-9
- Unique Ingredient Identifier
- 7V2F1075HD
- Background
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
- Associated Conditions
- -
- Associated Therapies
- -
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies
The T-cell malignancies market is expanding due to increased incidence, treatment advancements, and strategic partnerships. Key companies like Corvus Pharmaceuticals, Bristol-Myers Squibb, and Kymera Therapeutics are developing over 80 pipeline therapies. Notable drugs include Soquelitinib (Phase III), MB 105 (Phase II), and KT-333 (Phase I). Regulatory milestones and positive trial results are driving progress in this field.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath